Mode
Text Size
Log in / Sign up

PAP therapy reduces pulmonary arterial pressures in patients with severe OSA or OHS

PAP therapy reduces pulmonary arterial pressures in patients with severe OSA or OHS
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider that PAP may reduce pulmonary arterial pressure in severe OSA/OHS, but evidence is of low certainty.

This systematic review and meta-analysis evaluated the impact of positive airway pressure (PAP) therapy on pulmonary arterial pressures in 733 patients with obstructive sleep apnoea (OSA) or obesity hypoventilation syndrome (OHS). The analysis compared post-PAP therapy measurements to pre-treatment baseline. The study population included 518 patients with OSA and 215 with OHS and concomitant OSA, with most patients having severe OSA.

PAP therapy was associated with a mean reduction in pulmonary arterial pressure of 5.96 mmHg (95% CI 3.20-8.73 mmHg; p<0.0001). In a subgroup of 233 patients with baseline pulmonary hypertension, the mean reduction was more pronounced at 11.41 mmHg (95% CI 8.66-14.15 mmHg; p<0.00001). Safety, tolerability, and discontinuation data were not reported.

Key limitations include high statistical heterogeneity across studies (I²>85%), differences in study designs and methodologies, and a patient population consisting mostly of individuals with severe OSA. Consequently, the findings may not apply to patients with milder degrees of OSA. The authors rated the overall certainty of evidence as low.

Given the low certainty of evidence and high heterogeneity, cautious application of these findings in clinical practice is warranted. The analysis suggests an association between PAP therapy and reduced pulmonary arterial pressures, particularly in patients with baseline pulmonary hypertension, but does not establish causality.

Study Details

Study typeMeta analysis
Sample sizen = 518
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: There is limited and conflicting evidence on the impact of obstructive sleep apnoea (OSA) and its treatment with positive airway pressure (PAP) therapy on pulmonary hypertension (PH). Our research question was: does treatment of OSA and obesity hypoventilation syndrome (OHS) with PAP therapy improve pulmonary arterial pressures? METHODS: A systematic review and random effects meta-analysis was performed (PROSPERO: CRD42024595312). PubMed, Embase, Scopus, Web of Science, EBSCO, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov were searched using the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. Studies reporting pulmonary arterial pressure in patients with OSA and OHS pre- and post-PAP therapy were included. The primary outcome was post-PAP therapy change in pulmonary arterial pressures, with separate analyses on pulmonary arterial systolic pressure and mean pulmonary arterial pressure. Sensitivity analysis was performed to assess the impact of PAP therapy in patients with only OSA or OHS. RESULTS: 23 studies (20 observational and three randomised controlled trials) with 733 patients were included (19 with OSA (n=518) and four with OHS and concomitant OSA (n=215)). Most patients had severe OSA. PAP therapy was associated with a mean reduction in pulmonary arterial pressure of 5.96 (95% CI 3.20-8.73) mmHg; p<0.0001. In patients with baseline PH (n=233), the reduction was 11.41 (95% CI 8.66-14.15) mmHg; p<0.00001. The beneficial effect of PAP therapy was similar in OSA and OHS. There was no sex difference in the impact of PAP therapy. Heterogeneity was high across studies (I>85%), reflecting differences in study design, patient populations and methodologies. CONCLUSIONS: PAP therapy reduces pulmonary arterial pressures in patients with mostly severe OSA or OHS, with a more pronounced effect in those with baseline PH. As such, our findings may not apply to patients with milder degrees of OSA. While reductions in pulmonary arterial pressures were observed in all groups, the low certainty necessitates cautious application of these findings in clinical practice.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.